in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Socma Testifies on Risks Involving Pharma Ingredient Imports
2:40 PM MST | November 7, 2007 | Chemical Week Editorial Staff
Socma’s bulk pharmaceutical task force chief John Dubeck testified last week at a House Energy & Commerce Committee’s subcommittee on oversight and investigation about risks associated with drugs imported into the U.S. There is a lack of government inspections of overseas facilities manufacturing active pharma ingredients (APIs) that go into drugs, Dubeck says. The majority of overseas facilities manufacturing APIs used in generic medications rarely see an FDA inspector after an initial inspection, and most overseas manufacturers of...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee